InO - A Retrospective Study of UK Patients With Leukaemia

A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study

The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.

Inclusion Criteria:

• Patients with relapsed/refractory ALL.
• Patients who initiated InO between 1st of June 2016 and date of data collection.
• Patients who accessed InO treatment via NHS commissioning, via the CUP, or via private purchase.
• Patient aged ≥18 years old at initiation of InO treatment

Exclusion Criteria:

• Patients initiated on treatment with InO at a different hospital than the ones selected in this study.
• Patients with <3 months of follow-up since index date, unless death occurs <3 months from index date.